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Abstract 
Mixed phenotype acute leukemia (MPAL) accounts 
for 2-5% of all acute leukemias (Weinberg OK et al., 
2010).  The World Health Organization (WHO) 
classification of hematopoietic and lymphoid tumors 
proposed a simpler diagnostic algorithm, which 
relies on fewer and more lineage-specific markers to 
define MPAL.  MPAL with t(9;22) and MLL 
rearrangement are now separate subtypes of MPAL 
and considered as distinct entities (Weir EG et al., 
2010). Recent molecular studies demonstrates 
frequent epigenetic regulatory genes and tumor 
suppressor genes frequently present in MPAL. 
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Disease 
Mixed phenotype acute leukemia (MPAL) is a rare 
disease and historically has been labeled by a variety 
of names including mixed lineage leukemia, bilineal 
leukemia and biphenotypic leukemia (Weinberg OK 
et al., 2010). Similar to other acute leukemias, 
patients with MPAL present with fatigue, infections, 
bleeding disorders and high number of circulating 
blasts (Weir EG et al., 2010). 
Epidemiology 
Mixed phenotype acute leukemia is a rare disease 
and comprises 2-5% of all acute leukemias.  A 
simpler diagnostic algorithm is now used to define 
mixed phenotype acute leukemia (MPAL) is used by 
the World Health Organization (WHO) (Borowitz 
MJ et al., 2008; Arber DA et al., 2016). 
Pathology 
Morphologically, blasts in MPAL are mostly 
medium sized with fine chromatin and indistinct to 
prominent nucleoli; however these blasts can show 
classical lymphoid features and appear smaller in 
size with very high nuclear to cytoplasmic ratios and 
variably condensed nuclear chromatin, or myeloid 
features with cytoplasmic granules, very fine nuclear 
chromatin and large prominent nucleoli.  The 
diagnosis of MPAL rests on the immunophenotypic 
features of these blasts rather than morphology and 
flow cytometry is the preferred method for 
diagnosing MPAL. 
The WHO classification proposed a simpler 
diagnostic algorithm to define MPAL, which relies 
on fewer, more lineage specific markers.  Myeloid 
lineage requires the presence of myeloperoxidase as 
detected by flow cytometry, immunohistochemistry 
or cytochemistry or evidence of monocytic 
differentiation (with at least 2 of the following 
markers being positive: non-specific esterase 
cytochemistry, CD11c, CD14, CD64) (Borowitz MJ 
et al., 2008).  T-lineage can be shown with 
Mixed phenotype acute leukemia (MPAL)  
 
Atlas Genet Cytogenet Oncol Haematol. 2018; 22(7) 293 
 
cytoplasmic or surface CD3, at least as intense as 
background reactive T-cells, and multiple antigens 
are required for B-lineage including CD19, CD79a, 
CD22 and CD10 (Borowitz MJ et al.,  2008).  All 
possible combinations of MPAL can be observed 
including B/myeloid, T/myeloid, B/T or even rarely 
B/T/Myeloid (Borowitz MJ et al., 2008).  MPAL 
with t(9;22) and MLL rearrangement have been 
separated out as distinct subtypes.   
 
In the 2016 revision to the WHO classification, no 
new entities were defined within this group of 
leukemias.  Although the list of lineage specific 
markers is unchanged, it is now emphasized that in 
cases with 2 distinct blast populations each 
population should meet criteria for B-lymphoblastic 
leukemia (B-ALL), T-ALL or acute myeloid 
leukemia but it is not necessary that specific markers 
are present (Arber DA et al., 2016).  It is also now 
more specifically stated that cases of otherwise 
typical B-ALL with only low level expression of 
MPO (without other evidence of myeloid 
differentiation) should not be classified as MPAL 
(Arber DA et al., 2016).  Furthermore, a specific 
statement is now included that cases of otherwise 
typical ALL or AML do not need to meet the strict 
lineage defining criteria listed for MPAL 
Cytogenetics 
MPAL with BCR/ABL1 fusion gene   
 
MPAL with t(9;22)(q34;q11.2) or BCR/ABL1 
rearrangement  is considered as a separate entity 
(Borowitz MJ et al.,  2008; Arber DA et al., 2016). 
The t(9;22)(q34;q11.2 translocation results in a BCR 
/ ABL1 fusion gene located on the Philadelphia 
chromosome (Ph), causing a constitutively active 
BCR/ABL1 tyrosine kinase.  Acute leukemia with 
t(9;22) and blast phase of chronic myeloid leukemia 
(CML) have very similar clinical presentations and 
morphologic features and caution should be used 
when making a diagnosis. Splenomegaly, peripheral 
leukocytosis due to maturing myeloid precursors and 
mature neutrophils, absolute basophilia, and a 
clinical history of CML may support the diagnosis of 
blast phase of CML with MPAL phenotype (Arber 
DA et al., 2016). De novo MPAL with BCR/ABL1 
rearrangement generally occurs more frequent in 
older patients. Although most studies found the 
frequency of MPAL with t(9;22) to be 28-35%, 
pediatric studies report it to be much lower at 3% 
(Al-Seraihy AS et al., 2009). Many of these cases 
show a dimorphic population of blasts, with most 
showing B and myeloid lineage (Al-Seraihy AS et 
al., 2009; Killick S et al., 1999).  
 
MPAL with MLL rearrangement  
 
The second most frequent genetic lesion in MPAL 
includes translocations involving KMT2A (MLL) 
gene.  MLL rearrangement juxtaposes the amino-
terminus of the histone methyltransferase MLL to a 
variety of fusion partners, with the most common 
partner gene being AFF1 (AF4) on chromosome 4 
band q21.35 in MPAL (Xu XQ et al., 2009). This 
tends to occur more commonly in children and is 
more frequent in infancy (Xu XQ et al., 2009). These 
cases also tend to present with a dimorphic blast 
population, one resembling lymphoblasts and the 
other resembling monoblasts. By flow cytometry, 
the lymphoblasts usually have a CD19-positive, 
CD10-negative, B-precursor immunophenotype and 
are frequently positive for CD15.  Usually, the flow 
cytometry identify a separate population of myeloid 
blasts with monocytic differentiation. 
Genes 
Information regarding the mutational landscape of 
MPAL is based on small studies. Yan et al analyzed 
31 patients with MPAL and reported that 12 patients 
(39%) were found to harbor a known mutation (Yan 
L et al., 2012).  These included IKZF1 deletion in 4 
patients (all B-myeloid phenotype with evidence of 
BCR/ABL1 fusion gene), EZH2 in 3 (B- or T-
myeloid; one case showing complex karyotype and 
another showing loss of chromosome 7), ASXL1 in 
2 (both B-myeloid), TET2 in one (B-myeloid), and 
ETV6 and NOTCH1 in 1 patient each (both T-
myeloid) (Yan L et al., 2012).  No evidence of 
mutations in CBL, DNMT3A, FBXW7, FLT3, 
IDH1, IDH2, KIT, NPM1, PHF6, RUNX1, and WT1 
were found in Yan's study (Yan L et al., 2012).  
Tumor suppressors were also frequently mutated 
(22%).  
 
Whole-exome sequencing in 23 adult and pediatric 
patients with MPAL demonstrated that 35% patients 
had mutations in epigenetic regulatory genes 
(Eckstein OS et al., 2016). DNMT3A was the most 
common mutation (23%) followed by IDH2 (9%), 
TET3 (4%) and EZH2 (9%).  All of the DNMT3A 
mutations involved the methyltransferase domain, 
three of which were missense mutations at Arg882, 
the hotspot common in AML.  DNMT3A occurred 
in all immunophenotypic subtypes examined 
 
Mutations of DNMT3A and tumor suppressors 
showed high variant allele frequency (VAF) 
suggesting that these mutations arise early in disease.  
61% patients also had mutually exclusive mutations 
of activating signaling genes including NRAS, 
KRAS and NF1 (Gerr H et al., 2010).  NOTCH1 
mutations were present in 5 of 16 (32%) with T-
myeloid and B/T leukemia.  Three samples (13%) 
also had WT1 mutations. 
Treatment 
As a result of the absence of prospective trials, there 
is no set therapy for MPAL patients.  A few studies 
compared outcome of MPAL patients with that of 
matched control ALL or AML groups and most 
found that MPAL patients did worse than AML or 
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ALL (Weinberg OK et al., 2010).  In a study of 61 
patients, Weinberg et al., found that when compared 
with 177 patients with acute myeloid leukemia 
(AML), MPAL patients had better overall survival 
(P = .0003) and progression-free survival (P = .0001) 
(Weinberg OK et al., 2014). However, no difference 
in overall survival between MPAL and 387 patients 
with acute lymphoblastic leukemia was present (P = 
.599) (Weinberg OK et al., 2014).  For patients with 
t(9;22)-positive MPAL, a tyrosine kinase inhibitor 
(TKI) is usually added to treatment (Wolach O et al., 
2015).  In his review, Wolach et al suggested that the 
best approach for the non-t(9;22) MPAL patient is to 
treat with an ALL regimen and consolidate with an 
allogeneic stem cell transplant if a donor is available 
(Wolach O et al., 2015).  Shimizu H et al., has 
suggested that allogeneic hematopoietic stem cell 
transplantation maybe an effective treatment for 
MPAL patients, especially early in the disease 
course (Shimizu H et al., 2015). 
Prognosis 
In the few larger retrospective series of MPAL, the 
median overall survival is reported to range from 
14.8 to 18 months and rate of achieving long term 
survival in patients with adult MPAL is poor (<20%) 
(Matutes E et al., 2011; Deffis-Court M et al., 2014). 
Most of the retrospective case series suggest that the 
complete remission rates are higher with ALL 
therapy or an ALL/AML combined regimen than 
with AML-type therapy (Liu QF et al., 2013; Gerr H 
et al., 2010). 
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